Events Archives - Page 30 of 128

4 minute read

Century Therapeutics To Present Initial Clinical Data Supporting The Potential For A Multi-Dosing Strategy For CAR iNK Enabled By Allo-Evasion Edits At The 65th ASH Annual Meeting And Exposition

November 2, 9:18 AM

– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support, and a safety switch – –

IPSC

6 minute read

Geron IMerge Phase 3 Presentations At Upcoming ASH Annual Meeting Reinforce Significant Durability And Breadth Of Effect Of Imetelstat In Lower Risk MDS

By Benzinga Newsdesk

November 2, 9:17 AM

Subgroup analyses showed consistently higher transfusion independence (TI) response rates than placebo across different risk groups regardless of International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R) or

GERN

3 minute read

Jasper Therapeutics Announces Oral Presentation Of Final Results From Phase 1 Study Of Briquilimab In Patients With AML Or MDS Undergoing Hematopoietic Cell Transplant At ASH 2023

By Benzinga Newsdesk

November 2, 9:16 AM

Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic

JSPR

3 minute read

Gracell Biotechnologies To Present Updated Results From BCMA/CD19 Dual-Targeting FasTCAR-T GC012F In Newly Diagnosed Multiple Myeloma At The 65 American Society Of Hematology Annual Meeting & Exposition

By Benzinga Newsdesk

November 2, 9:15 AM

Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma GC012F is a

GRCL

4 minute read

Autolus Therapeutics To Present Clinical Data Updates At The American Society Of Hematology Annual Meeting 2023 In Two Oral Presentations And Two Poster Presentations

By Benzinga Newsdesk

November 2, 9:13 AM

obe-cel: oral presentation – pooled analysis of the ongoing FELIX Phase Ib/II studyAUTO8: oral presentation of MCARTY Phase I Studyobe-cel: poster presentation - pooled analysis from ALLCAR19 and FELIX Phase Ib studies

AUTL

1 minute read

ORIC Pharmaceuticals To Present Initial Phase 1b Clinical Data For ORIC-533 In Multiple Myeloma At The 65th American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

November 2, 9:12 AM

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation on the initial Phase

ORIC

2 minute read

Lexicon Pharmaceuticals Announces Data On Early Clinical Benefit For INPEFA Will Be Among Five Lexicon-Sponsored Presentations At The American Heart Association Scientific Sessions 2023

By Benzinga Newsdesk

November 2, 9:12 AM

Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentationINPEFA® (sotagliflozin) recently

LXRX

3 minute read

Disc Medicine Announces Multiple Presentations Across Portfolio At The 65th American Society Of Hematology Annual Meeting And Key Program Updates

By Benzinga Newsdesk

November 2, 9:11 AM

Completion of enrollment for phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP)Oral presentation at ASH meeting of updated interim data from BEACON, including a preliminary analysis of

IRON

3 minute read

Kymera Therapeutics To Present New Clinical Data From The Phase 1 Trial Of STAT3 Degrader KT-333 At The ASH Annual Meeting

By Benzinga Newsdesk

November 2, 9:10 AM

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through July 10, 2023 cut-off Updated data to be presented at the American Society of Hematology (ASH) 65th Annual

KYMR

2 minute read

Schrödinger To Present New Data For SGR-1505 And SGR-2921 At American Society Of Hematology 2023 Annual Meeting

By Benzinga Newsdesk

November 2, 9:08 AM

Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new data on SGR-1505, its investigational MALT1 inhibitor, and

SDGR